Search

Your search keyword '"Elalamy, I."' showing total 616 results
Start Over Author "Elalamy, I."
616 results on '"Elalamy, I."'

4. PB1442 Clinical Significance of PAI-I, F2 Thr165Met Genes Polymorphisms in Pregnant Women with a History of Thrombosis

Author

Babaeva, N., primary, Khizroeva, J., additional, Bitsadze, V., additional, Tretyakova, M., additional, Elalamy, I., additional, Makatsariya, N., additional, Nakaidze, I., additional, Vorobev, A., additional, Zabolotnaya, D., additional, Blbulyan, D., additional, Alkhimova, A., additional, Khalieva, K., additional, Pervushina, A., additional, and Makatsariya, A., additional

Published
2023
Full Text
View/download PDF

5. PB0081 von Willebrand Factor and Myeloperoxidase as Laboratory Predictive Markers of In-Hospital Survival in Severe COVID-19 Patients

Author

Makatsariya, A., primary, Bitsadze, V., additional, Khizroeva, J., additional, Pankratyeva, L., additional, Gris, J., additional, Elalamy, I., additional, Tretyakova, M., additional, Kristina, G., additional, Aslanova, Z., additional, Gashimova, N., additional, Nakaidze, I., additional, Zabolotnaya, D., additional, Pervushina, A., additional, Blbulyan, D., additional, Lazarchuk, A., additional, and Salnikova, P., additional

Published
2023
Full Text
View/download PDF

8. PB0086 Prospective Assessment of Thrombomodulin Resistance in Oncological Patients and Healthy Subjects Following Vaccination Against Sars-Cov-2 with the mRNAVaccine. The Roadmap-COVID-19-Vaccin Study

Author

Van Dreden, P., primary, Gligorov, J., additional, Terpos, E., additional, Jamelot, M., additional, Grussé, M., additional, Elalamy, I., additional, Fareed, J., additional, Rousseau, A., additional, Dimopoulos, M., additional, and Gerotziafas, G., additional

Published
2023
Full Text
View/download PDF

9. Neutrophil extracellular traps-associated markers in malignant neoplasms of the female reproductive system after surgical treatment and adjuvant chemotherapy

Author

Slukhanchuk, E. V., primary, Bitsadze, V. O., additional, Solopova, A. G., additional, Khizroeva, J. Kh., additional, Gris, J.-K., additional, Elalamy, I., additional, Degtyareva, N. D., additional, Gileva, M. A., additional, Samburova, N. V., additional, Shcherbakov, D. V., additional, Yakubova, F. E., additional, Zelepukhina, M. E., additional, Blinov, D. V., additional, and Makatsariya, A. D., additional

Published
2023
Full Text
View/download PDF

13. POS1513 IDENTIFYING HIGH-RISK PROFILE IN PRIMARY ANTIPHOSPHOLIPID SYNDROME THROUGH CLUSTER ANALYSIS: FRENCH MULTICENTRIC COHORT STUDY

Author

Guedon, A. F., primary, Ricard, L., additional, Charlotte, L., additional, De Moreuil, C., additional, Urbanski, G., additional, Deriaz, S., additional, Gerotziafas, G., additional, Elalamy, I., additional, Audemard, A., additional, Chasset, F., additional, Alamowitch, S., additional, Sellam, J., additional, Boffa, J. J., additional, Cohen, A., additional, Wahl, C., additional, Abisror, N., additional, Maillot, F., additional, Fain, O., additional, and Mekinian, A., additional

Published
2023
Full Text
View/download PDF

14. AB0582 DESCRIPTION OF ASYMPTOMATIC ANTI-PHOSPHOLIPID CARRIERS IN A FRENCH MULTICENTER COHORT STUDY

Author

Nigolian, H., primary, Guedon, A., additional, Allali, D., additional, Laurent, C., additional, Ricard, L., additional, Yann, N., additional, Boffa, J. J., additional, Rondeau, E., additional, Gerotziafas, G., additional, Elalamy, I., additional, Deriaz, S., additional, De Moreuil, C., additional, Planche, V., additional, Johanet, C., additional, Maillot, F., additional, Fain, O., additional, and Mekinian, A., additional

Published
2023
Full Text
View/download PDF

15. Hemostasis parameters as prognostic biomarkers in gynecological cancer patients

Author

Slukhanchuk, E. V., primary, Bitsadze, V. O., additional, Solopova, A. G., additional, Khizroeva, J. Kh., additional, Gris, J.-C., additional, Elalamy, I., additional, Shcherbakov, D. V., additional, Shkoda, A. S., additional, Pankratyeva, L. L., additional, Ungiadze, J. Yu., additional, Ashrafyan, L. A., additional, and Makatsariya, A. D., additional

Published
2023
Full Text
View/download PDF

17. Antithrombotic therapy in COVID-19 patients

Author

Slukhanchuk, E. V., primary, Bitsadze, V. O., additional, Khizroeva, J. Kh., additional, Tretyakova, M. V., additional, Shkoda, A. S., additional, Blinov, D. V., additional, Tsibizova, V. I., additional, Jinbo, Z., additional, Sheena, S., additional, Sсhulman, S., additional, Gris, J.-K., additional, Elalamy, I., additional, and Makatsariya, A. D., additional

Published
2023
Full Text
View/download PDF

18. Immunothrombosis in cancer patients: contribution of neutrophil extracellular traps, ADAMTS-13 and von Willebrand factor

Author

Slukhanchuk, E. V., primary, Bitsadze, V. O., additional, Solopova, A. G., additional, Khizroeva, J. Kh., additional, Tsibizova, V. I., additional, Gris, J.-K., additional, Elalamy, I., additional, Shcherbakov, D. V., additional, Pankratyeva, L. L., additional, Ashrafyan, L. A., additional, and Makatsariya, A. D., additional

Published
2023
Full Text
View/download PDF

19. Dysregulated platelet function in COVID-19 patients

Author

Gashimova, N. R., primary, Bitsadze, V. O., additional, Pankratyeva, L. L., additional, Khizroeva, J. Kh., additional, Slukhanchuk, E. V., additional, Grigoreva, K. N., additional, Tsibizova, V. I., additional, Gris, J.-C., additional, Elalamy, I., additional, Ay, C., additional, Blinov, D. V., additional, Serov, V. N., additional, and Makatsariya, A. D., additional

Published
2023
Full Text
View/download PDF

20. Analyse exploratoire des profils à haut risque dans le syndrome primaire des antiphospholipides par l’analyse de clusters : étude de cohorte multicentrique française

Author

Guédon, A.F., primary, Ricard, L., additional, Laurent, C., additional, De Moreuil, C., additional, Urbansky, G., additional, Deriaz, S., additional, Gerotziafas, G., additional, Elalamy, I., additional, Alexandra, A.V., additional, Chasset, F., additional, Alamowitch, S., additional, Sellam, J., additional, Boffa, J.J., additional, Cohen, A., additional, Abisror, N., additional, Maillot, F., additional, Fain, O., additional, and Mekinian, A., additional

Published
2022
Full Text
View/download PDF

21. Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides

Author

Nigolian, H., primary, Guédon, A.F., additional, Allali, D., additional, Laurent, C., additional, Ricard, L., additional, Nguyen, Y., additional, Boffa, J.J., additional, Rondeau, E., additional, Gerotziafas, G., additional, Elalamy, I., additional, Deriaz, S., additional, De Moreuil, C., additional, Planche, V., additional, Johanet, C., additional, Maillot, F., additional, Fain, O., additional, and Mekinian, A., additional

Published
2022
Full Text
View/download PDF

22. Profil clinicobiologique et pronostic des patients porteurs asymptomatiques d’anticorps du SAPL : une étude de cohorte multicentrique française

Author

Guédon, A.F., primary, Nigolian, H., additional, Allali, D., additional, Laurent, C., additional, Ricard, L., additional, Nguyen, Y., additional, Boffa, J.J., additional, Rondeau, E., additional, Gerotziafas, G., additional, Elalamy, I., additional, Deriaz, S., additional, De Moreuil, C., additional, Planche, V., additional, Wahl, C., additional, Johanet, C., additional, Maillot, F., additional, Fain, O., additional, and Mekinian, A., additional

Published
2022
Full Text
View/download PDF

24. New orally active anticoagulant agents for the prevention and treatment of venous thromboembolism in cancer patients

Author

Gerotziafas GT, Mahé I, and Elalamy I

Subjects
Therapeutics. Pharmacology, RM1-950
Abstract

Grigoris T Gerotziafas,1,2 Isabelle Mahé,3 Ismail Elalamy1,21Service d'Hématologie Biologique, Hôpital Tenon, Hôpitaux Universitaires Est Parisien Assistance Publique Hôpitaux de Paris, Paris, France; 2ER2UPMC, Faculté de Médecine Pierre et Marie Curie, Université Paris VI, Paris, France; 3Service de Médecine interne, Hôpital Louis Mourier, Universite´ Paris 7, Assistance Publique Hôpitaux de Paris, EA REMES Université Paris Diderot, Sorbonne Paris Cité, Paris,FranceAbstract: Patients with cancer have a 6–7-fold higher risk of venous thromboembolism (VTE) as compared with non-cancer patients. Effective and safe anticoagulation for the prevention and treatment of VTE is the cornerstone of the management of patients with cancer, aiming to decrease morbidity and mortality and to improve quality of life. Unfractionated heparin, low molecular weight heparins, fondaparinux and vitamin K antagonists (VKAs) are used in the prevention and treatment of VTE in cancer patients. Heparins and fondaparinux are administered subcutaneously. VKAs are orally active, but they have a narrow therapeutic window, numerous food and drug interactions, and treatment requires regular laboratory monitoring and dose adjustment. These limitations among others have important negative impact on the quality of life of patients and decrease adherence to the treatment. New orally active anticoagulant (NOAC) agents are specific inhibitors of activated factor Xa (FXa) (rivaroxaban and apixaban) or thrombin (dabigatran). It is expected that NOACs will improve antithrombotic treatment. Cancer patients are a particular group that could benefit from treatment with NOACs. However, NOACs present some significant interactions with drugs frequently used in cancer patients, which might influence their pharmacokinetics, compromising their efficacy and safety. In the present review, we analyzed the available data from the subgroups of patients with active cancer who were included in Phase III clinical trials that assessed the efficacy and safety of NOACs in the prevention and treatment of VTE. The data from the Phase III trials in prophylaxis of VTE by rivaroxaban or apixaban highlight that these two agents, although belonging to the same pharmacological group (direct inhibitors of factor Xa), have substantially different profiles of efficacy and safety, especially in hospitalized acutely ill medical patients with active cancer. A limited number of patients with VTE and active cancer were included in the Phase III trials (EINSTEIN, AMPLIFY, and RE-COVER) which evaluated the efficacy and safety of NOACs in the acute phase and secondary prevention of VTE. Although, from a conceptual point of view, NOACs could be an attractive alternative for the treatment of VTE in cancer patients, the available data do not support this option. In addition, due to the elimination of the NOACs by the liver and renal pathway as well as because of their pharmacological interactions with drugs which are frequently used in cancer patients, an eventual use of these drugs in cancer patients should be extremely cautious and be restricted only to patients presenting with contraindications for low molecular weight heparins, fondaparinux, or VKAs. The analysis of the available data presented in this review reinforces the request for the design of new Phase III clinical trials for the assessment of the efficacy and safety of NOACs in specific populations of patients with cancer.Keywords: rivaroxaban, apixaban, dabigatran, antithrombotic treatment

Published
2014

25. Thromboinflammation in oncogynecological patients

Author

Slukhanchuk, E. V., primary, Bitsadze, V. O., additional, Solopova, A. G., additional, Khizroeva, J. Kh., additional, Gris, J.-S., additional, Elalamy, I., additional, Pankratyeva, L. L., additional, Tsibizova, V. I., additional, Ungiadze, J. Yu., additional, Ashrafyan, L. A., additional, and Makatsariya, A. D., additional

Published
2022
Full Text
View/download PDF

26. Prognostic value of von Willebrand factor in clinical practice

Author

Grigoreva, K. N., primary, Bitsadze, V. O., additional, Khizroeva, J. Kh., additional, Tsibizova, V. I., additional, Tretyakova, M. V., additional, Blinov, D. V., additional, Pankratyeva, L. L., additional, Gashimova, N. R., additional, Yakubova, F. E., additional, Antonova, A. S., additional, Gris, J.-C., additional, Elalamy, I., additional, and Makatsariya, A. D., additional

Published
2022
Full Text
View/download PDF

30. 1590P Interest of preventive treatment with anticoagulant in older patients with cancer on venous thrombo-embolic events (ANTIGONE study): Design and baseline results

Author

Hanon, O., primary, Paillaud, E., additional, Baudin, A., additional, Chaoui, S., additional, Canovas, J., additional, Iratni, L., additional, Lucas, P., additional, Mabungu, H., additional, Villebrun, M., additional, Chambraud, C., additional, Rollot-Trad, F., additional, Bringuier, M., additional, Broussier, A., additional, Spiess, N., additional, Elalamy, I., additional, and Canouï-Poitrine, F., additional

Published
2022
Full Text
View/download PDF

32. SARS-CoV-2 Vaccine and Thrombosis: An Expert Consensus on Vaccine-Induced Immune Thrombotic Thrombocytopenia

Author

Elalamy, I., Gerotziafas, G., Alamowitch, S., Laroche, J. -P., Van Dreden, P., Ageno, W., Beyer-Westendorf, J., Cohen, A. T., Jimenez, D., Brenner, B., Middeldorp, S., Cacoub, P., Lip, G. Y. H., Makris, M., Schulman, S., Siess, W., Weber, C., Vascular Medicine, ACS - Pulmonary hypertension & thrombosis, and ARD - Amsterdam Reproduction and Development

Subjects
medicine.medical_specialty, COVID-19 Vaccines, Eradication of infectious diseases, SARS-CoV-2, thrombosis, vaccination, VITT, COVID-19, Clinical Decision-Making, Hemorrhage, Humans, Purpura, Thrombocytopenic, Idiopathic, Risk Factors, Thrombocytopenia, Thrombosis, Vaccination, Vascular damage Radboud Institute for Health Sciences [Radboudumc 16], Population, 030204 cardiovascular system & hematology, 03 medical and health sciences, 0302 clinical medicine, Consensus Paper, Health care, Pandemic, medicine, 030212 general & internal medicine, Medical prescription, education, Intensive care medicine, Adverse effect, Purpura, education.field_of_study, business.industry, Idiopathic, Hematology, Guideline, Thrombocytopenic, 3. Good health, business
Abstract

Contains fulltext : 238068.pdf (Publisher’s version ) (Open Access) Historically, the vaccination strategies developed in the second half of the 20th century have facilitated the eradication of infectious diseases. From the onset of COVID-19 pandemic to the end of April 2021, more than 150 million cases and 3 million deaths were documented worldwide with disruption of the economic and social activity, and with devastating material, physical, and psychological consequences. Reports of unusual and severe thrombotic events, including cerebral and splanchnic venous thrombosis and other autoimmune adverse reactions, such as immune thrombocytopenia or thrombotic microangiopathies in connection with some of the SARS-CoV-2 vaccines, have caused a great deal of concern within the population and the medical community. This report is intended to provide practical answers following an overview of our knowledge on these thrombotic events that are extremely rare but have serious consequences. Vaccine hesitancy threatens to reverse the progress made in controlling vaccine-preventable diseases. These adverse events must be put into perspective with an objective analysis of the facts and the issues of the vaccination strategy during this SARS-CoV-2 pandemic. Health care professionals remain the most pertinent advisors and influencers regarding vaccination decisions; they have to be supported to provide reliable and credible information on vaccines. We need to inform, reassure, and support our patients when the prescription is made. Facing these challenges and observations, a panel of experts express their insights and propose a tracking algorithm for vaccinated patients based on a 10-point guideline for decision-making on what to do and not to do.

Published
2021
Full Text
View/download PDF

33. Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine

Author

Gerotziafas G. T., Catalano M., Colgan M. -P., Pecsvarady Z., Wautrecht J. C., Fazeli B., Olinic D. -M., Farkas K., Elalamy I., Falanga A., Fareed J., Papageorgiou C., Arellano R. S., Agathagelou P., Antic D., Auad L., Banfic L., Bartolomew J. R., Benczur B., Bernardo M. B., Boccardo F., Cifkova R., Cosmi B., De Marchi S., Dimakakos E., Dimopoulos M. A., Dimitrov G., Durand-Zaleski I., Edmonds M., El Nazar E. A., Erer D., Esponda O. L., Gresele P., Gschwandtner M., Gu Y., Heinzmann M., Hamburg N. M., Hamade A., Jatoi N. -A., Karahan O., Karetova D., Karplus T., Klein-Weigel P., Kolossvary E., Kozak M., Lefkou E., Lessiani G., Liew A., Marcoccia A., Marshang P., Marakomichelakis G., Matuska J., Moraglia L., Pillon S., Poredos P., Prior M., Salvador D. R. K., Schlager O., Schernthaner G., Sieron A., Spaak J., Spyropoulos A., Sprynger M., Suput D., Stanek A., Stvrtinova V., Szuba A., Tafur A., Vandreden P., Vardas P. E., Vasic D., Vikkula M., Wennberg P., Zhai Z., Bikdeli B., Guo Y., Harenberg J., Hu Y., Lip G. Y. H., Roldan V., Gerotziafas, G, Catalano, M, Colgan, M, Pecsvarady, Z, Wautrecht, J, Fazeli, B, Olinic, D, Farkas, K, Elalamy, I, Falanga, A, Fareed, J, Papageorgiou, C, Arellano, R, Agathagelou, P, Antic, D, Auad, L, Banfic, L, Bartolomew, J, Benczur, B, Bernardo, M, Boccardo, F, Cifkova, R, Cosmi, B, De Marchi, S, Dimakakos, E, Dimopoulos, M, Dimitrov, G, Durand-Zaleski, I, Edmonds, M, El Nazar, E, Erer, D, Esponda, O, Gresele, P, Gschwandtner, M, Gu, Y, Heinzmann, M, Hamburg, N, Hamade, A, Jatoi, N, Karahan, O, Karetova, D, Karplus, T, Klein-Weigel, P, Kolossvary, E, Kozak, M, Lefkou, E, Lessiani, G, Liew, A, Marcoccia, A, Marshang, P, Marakomichelakis, G, Matuska, J, Moraglia, L, Pillon, S, Poredos, P, Prior, M, Salvador, D, Schlager, O, Schernthaner, G, Sieron, A, Spaak, J, Spyropoulos, A, Sprynger, M, Suput, D, Stanek, A, Stvrtinova, V, Szuba, A, Tafur, A, Vandreden, P, Vardas, P, Vasic, D, Vikkula, M, Wennberg, P, Zhai, Z, Bikdeli, B, Guo, Y, Harenberg, J, Hu, Y, Lip, G, Roldan, V, Centre de Recherche Saint-Antoine (CR Saint-Antoine), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Trinity College Dublin, Hôpital Erasme [Bruxelles] (ULB), Faculté de Médecine [Bruxelles] (ULB), Université libre de Bruxelles (ULB)-Université libre de Bruxelles (ULB), Mashhad University of Medical Sciences, Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Conservatoire National des Arts et Métiers [CNAM] (CNAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Gerotziafas G.T., Catalano M., Colgan M.-P., Pecsvarady Z., Wautrecht J.C., Fazeli B., Olinic D.-M., Farkas K., Elalamy I., Falanga A., Fareed J., Papageorgiou C., Arellano R.S., Agathagelou P., Antic D., Auad L., Banfic L., Bartolomew J.R., Benczur B., Bernardo M.B., Boccardo F., Cifkova R., Cosmi B., De Marchi S., Dimakakos E., Dimopoulos M.A., Dimitrov G., Durand-Zaleski I., Edmonds M., El Nazar E.A., Erer D., Esponda O.L., Gresele P., Gschwandtner M., Gu Y., Heinzmann M., Hamburg N.M., Hamade A., Jatoi N.-A., Karahan O., Karetova D., Karplus T., Klein-Weigel P., Kolossvary E., Kozak M., Lefkou E., Lessiani G., Liew A., Marcoccia A., Marshang P., Marakomichelakis G., Matuska J., Moraglia L., Pillon S., Poredos P., Prior M., Salvador D.R.K., Schlager O., Schernthaner G., Sieron A., Spaak J., Spyropoulos A., Sprynger M., Suput D., Stanek A., Stvrtinova V., Szuba A., Tafur A., Vandreden P., Vardas P.E., Vasic D., Vikkula M., Wennberg P., Zhai Z., Bikdeli B., Guo Y., Harenberg J., Hu Y., Lip G.Y.H., Roldan V., and UCL - SSS/DDUV/GEHU - Génétique

Subjects
030204 cardiovascular system & hematology, antithrombotic, antiplatelet, chemistry.chemical_compound, 0302 clinical medicine, Rivaroxaban, Risk Factors, cardiovascular disease, Thrombophilia, 030212 general & internal medicine, antiplatelets, low-molecular-weight heparin, Societies, Medical, Low-Molecular-Weight, Hematology, 3. Good health, Europe, Cardiovascular Diseases, Thrombosi, Practice Guidelines as Topic, Position Paper, Risk assessment, medicine.drug, Human, medicine.medical_specialty, anticoagulants, medicine.drug_class, DOAC, Cardiology, Low molecular weight heparin, peripheral artery disease, deep vein thrombosis, 03 medical and health sciences, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Medical, medicine, Humans, COVID-19 - cardiovascular disease - peripheral artery disease - deep vein thrombosis - antithrombotic - antiplatelets - anticoagulants - low-molecular-weight heparin - DOAC, Intensive care medicine, Contraindication, Angiology, Inflammation, Vascular disease, business.industry, Heparin, SARS-CoV-2, Risk Factor, anticoagulant, deep vein thrombosi, COVID-19, Thrombosis, Heparin, Low-Molecular-Weight, medicine.disease, COVID-19 Drug Treatment, chemistry, Betrixaban, business, Societies
Abstract

COVID-19 is also manifested with hypercoagulability, pulmonary intravascular coagulation, microangiopathy, and venous thromboembolism (VTE) or arterial thrombosis. Predisposing risk factors to severe COVID-19 are male sex, underlying cardiovascular disease, or cardiovascular risk factors including noncontrolled diabetes mellitus or arterial hypertension, obesity, and advanced age. The VAS-European Independent Foundation in Angiology/Vascular Medicine draws attention to patients with vascular disease (VD) and presents an integral strategy for the management of patients with VD or cardiovascular risk factors (VD-CVR) and COVID-19. VAS recommends (1) a COVID-19-oriented primary health care network for patients with VD-CVR for identification of patients with VD-CVR in the community and patients' education for disease symptoms, use of eHealth technology, adherence to the antithrombotic and vascular regulating treatments, and (2) close medical follow-up for efficacious control of VD progression and prompt application of physical and social distancing measures in case of new epidemic waves. For patients with VD-CVR who receive home treatment for COVID-19, VAS recommends assessment for (1) disease worsening risk and prioritized hospitalization of those at high risk and (2) VTE risk assessment and thromboprophylaxis with rivaroxaban, betrixaban, or low-molecular-weight heparin (LMWH) for those at high risk. For hospitalized patients with VD-CVR and COVID-19, VAS recommends (1) routine thromboprophylaxis with weight-adjusted intermediate doses of LMWH (unless contraindication); (2) LMWH as the drug of choice over unfractionated heparin or direct oral anticoagulants for the treatment of VTE or hypercoagulability; (3) careful evaluation of the risk for disease worsening and prompt application of targeted antiviral or convalescence treatments; (4) monitoring of D-dimer for optimization of the antithrombotic treatment; and (5) evaluation of the risk of VTE before hospital discharge using the IMPROVE-D-dimer score and prolonged post-discharge thromboprophylaxis with rivaroxaban, betrixaban, or LMWH.

Published
2020
Full Text
View/download PDF

34. Anticoagulants: dose control methods and inhibitors

Author

Bitsadze, V. O., primary, Slukhanchuk, E. V., additional, Khizroeva, J. Kh., additional, Tretyakova, M. V., additional, Gashimova, N. R., additional, Nakaidze, I. A., additional, Elalamy, I., additional, Gris, J.-Kh., additional, and Makatsariya, A. D., additional

Published
2022
Full Text
View/download PDF

35. Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine

Author

Gerotziafas, G, Catalano, M, Colgan, M, Pecsvarady, Z, Wautrecht, J, Fazeli, B, Olinic, D, Farkas, K, Elalamy, I, Falanga, A, Fareed, J, Papageorgiou, C, Arellano, R, Agathagelou, P, Antic, D, Auad, L, Banfic, L, Bartolomew, J, Benczur, B, Bernardo, M, Boccardo, F, Cifkova, R, Cosmi, B, De Marchi, S, Dimakakos, E, Dimopoulos, M, Dimitrov, G, Durand-Zaleski, I, Edmonds, M, El Nazar, E, Erer, D, Esponda, O, Gresele, P, Gschwandtner, M, Gu, Y, Heinzmann, M, Hamburg, N, Hamade, A, Jatoi, N, Karahan, O, Karetova, D, Karplus, T, Klein-Weigel, P, Kolossvary, E, Kozak, M, Lefkou, E, Lessiani, G, Liew, A, Marcoccia, A, Marshang, P, Marakomichelakis, G, Matuska, J, Moraglia, L, Pillon, S, Poredos, P, Prior, M, Salvador, D, Schlager, O, Schernthaner, G, Sieron, A, Spaak, J, Spyropoulos, A, Sprynger, M, Suput, D, Stanek, A, Stvrtinova, V, Szuba, A, Tafur, A, Vandreden, P, Vardas, P, Vasic, D, Vikkula, M, Wennberg, P, Zhai, Z, Bikdeli, B, Guo, Y, Harenberg, J, Hu, Y, Lip, G, Roldan, V, Gerotziafas G. T., Catalano M., Colgan M. -P., Pecsvarady Z., Wautrecht J. C., Fazeli B., Olinic D. -M., Farkas K., Elalamy I., Falanga A., Fareed J., Papageorgiou C., Arellano R. S., Agathagelou P., Antic D., Auad L., Banfic L., Bartolomew J. R., Benczur B., Bernardo M. B., Boccardo F., Cifkova R., Cosmi B., De Marchi S., Dimakakos E., Dimopoulos M. A., Dimitrov G., Durand-Zaleski I., Edmonds M., El Nazar E. A., Erer D., Esponda O. L., Gresele P., Gschwandtner M., Gu Y., Heinzmann M., Hamburg N. M., Hamade A., Jatoi N. -A., Karahan O., Karetova D., Karplus T., Klein-Weigel P., Kolossvary E., Kozak M., Lefkou E., Lessiani G., Liew A., Marcoccia A., Marshang P., Marakomichelakis G., Matuska J., Moraglia L., Pillon S., Poredos P., Prior M., Salvador D. R. K., Schlager O., Schernthaner G., Sieron A., Spaak J., Spyropoulos A., Sprynger M., Suput D., Stanek A., Stvrtinova V., Szuba A., Tafur A., Vandreden P., Vardas P. E., Vasic D., Vikkula M., Wennberg P., Zhai Z., Bikdeli B., Guo Y., Harenberg J., Hu Y., Lip G. Y. H., Roldan V., Gerotziafas, G, Catalano, M, Colgan, M, Pecsvarady, Z, Wautrecht, J, Fazeli, B, Olinic, D, Farkas, K, Elalamy, I, Falanga, A, Fareed, J, Papageorgiou, C, Arellano, R, Agathagelou, P, Antic, D, Auad, L, Banfic, L, Bartolomew, J, Benczur, B, Bernardo, M, Boccardo, F, Cifkova, R, Cosmi, B, De Marchi, S, Dimakakos, E, Dimopoulos, M, Dimitrov, G, Durand-Zaleski, I, Edmonds, M, El Nazar, E, Erer, D, Esponda, O, Gresele, P, Gschwandtner, M, Gu, Y, Heinzmann, M, Hamburg, N, Hamade, A, Jatoi, N, Karahan, O, Karetova, D, Karplus, T, Klein-Weigel, P, Kolossvary, E, Kozak, M, Lefkou, E, Lessiani, G, Liew, A, Marcoccia, A, Marshang, P, Marakomichelakis, G, Matuska, J, Moraglia, L, Pillon, S, Poredos, P, Prior, M, Salvador, D, Schlager, O, Schernthaner, G, Sieron, A, Spaak, J, Spyropoulos, A, Sprynger, M, Suput, D, Stanek, A, Stvrtinova, V, Szuba, A, Tafur, A, Vandreden, P, Vardas, P, Vasic, D, Vikkula, M, Wennberg, P, Zhai, Z, Bikdeli, B, Guo, Y, Harenberg, J, Hu, Y, Lip, G, Roldan, V, Gerotziafas G. T., Catalano M., Colgan M. -P., Pecsvarady Z., Wautrecht J. C., Fazeli B., Olinic D. -M., Farkas K., Elalamy I., Falanga A., Fareed J., Papageorgiou C., Arellano R. S., Agathagelou P., Antic D., Auad L., Banfic L., Bartolomew J. R., Benczur B., Bernardo M. B., Boccardo F., Cifkova R., Cosmi B., De Marchi S., Dimakakos E., Dimopoulos M. A., Dimitrov G., Durand-Zaleski I., Edmonds M., El Nazar E. A., Erer D., Esponda O. L., Gresele P., Gschwandtner M., Gu Y., Heinzmann M., Hamburg N. M., Hamade A., Jatoi N. -A., Karahan O., Karetova D., Karplus T., Klein-Weigel P., Kolossvary E., Kozak M., Lefkou E., Lessiani G., Liew A., Marcoccia A., Marshang P., Marakomichelakis G., Matuska J., Moraglia L., Pillon S., Poredos P., Prior M., Salvador D. R. K., Schlager O., Schernthaner G., Sieron A., Spaak J., Spyropoulos A., Sprynger M., Suput D., Stanek A., Stvrtinova V., Szuba A., Tafur A., Vandreden P., Vardas P. E., Vasic D., Vikkula M., Wennberg P., Zhai Z., Bikdeli B., Guo Y., Harenberg J., Hu Y., Lip G. Y. H., and Roldan V.

Abstract

COVID-19 is also manifested with hypercoagulability, pulmonary intravascular coagulation, microangiopathy, and venous thromboembolism (VTE) or arterial thrombosis. Predisposing risk factors to severe COVID-19 are male sex, underlying cardiovascular disease, or cardiovascular risk factors including noncontrolled diabetes mellitus or arterial hypertension, obesity, and advanced age. The VAS-European Independent Foundation in Angiology/Vascular Medicine draws attention to patients with vascular disease (VD) and presents an integral strategy for the management of patients with VD or cardiovascular risk factors (VD-CVR) and COVID-19. VAS recommends (1) a COVID-19-oriented primary health care network for patients with VD-CVR for identification of patients with VD-CVR in the community and patients' education for disease symptoms, use of eHealth technology, adherence to the antithrombotic and vascular regulating treatments, and (2) close medical follow-up for efficacious control of VD progression and prompt application of physical and social distancing measures in case of new epidemic waves. For patients with VD-CVR who receive home treatment for COVID-19, VAS recommends assessment for (1) disease worsening risk and prioritized hospitalization of those at high risk and (2) VTE risk assessment and thromboprophylaxis with rivaroxaban, betrixaban, or low-molecular-weight heparin (LMWH) for those at high risk. For hospitalized patients with VD-CVR and COVID-19, VAS recommends (1) routine thromboprophylaxis with weight-adjusted intermediate doses of LMWH (unless contraindication); (2) LMWH as the drug of choice over unfractionated heparin or direct oral anticoagulants for the treatment of VTE or hypercoagulability; (3) careful evaluation of the risk for disease worsening and prompt application of targeted antiviral or convalescence treatments; (4) monitoring of D-dimer for optimization of the antithrombotic treatment; and (5) evaluation of the risk of VTE before hospital dischar

Published
2020

36. Features of the novel coronavirus infection in cancer patients

Author

Makatsariya, A. D., primary, Elalamy, I., additional, Brenner, B., additional, Vorobev, A. V., additional, Ashrafyan, L. A., additional, Maslenkova, E. V., additional, Bitsadze, V. O., additional, Khizroeva, J. Kh., additional, Shkoda, A. S., additional, Solopova, A. G., additional, Galkin, V. N., additional, and Gris, J.-C., additional

Published
2022
Full Text
View/download PDF

37. Manifestations non-criteria dans le syndrome des antiphospholipides: une étude cas-témoin multicentrique rétrospective française

Author

Guedon, A., primary, Catano, J., additional, Ricard, L., additional, Laurent, C., additional, De Moreuil, C., additional, Urbansky, G., additional, Deriaz, S., additional, Gerotziafas, G., additional, Elalamy, I., additional, Alexandra, A.V., additional, Chasset, F., additional, Alamowitch, S., additional, Sellam, J., additional, Maillot, F., additional, Boffa, J.J., additional, Cohen, A., additional, Abisror, N., additional, Fain, O., additional, and Mekinian, A., additional

Published
2021
Full Text
View/download PDF

40. Evaluation of flow cytometric assay in the diagnosis of HIT: OR055

Author

Tardy, B, Montmartin, A, Piot, M, Chapelle, C, Akrour, M, Alhenc-Gelas, M, Maistre, E D, Elalamy, I, Fontana, P, Greinacher, A, Horellou, M-H, Lasne, D, Lecompte, T, Legal, G, Lillo-LeLouet, A, Mullier, F, Nguyen, P, Pouplard, C, Toussaint-Hacquard, M, and Tomer, A

Published
2015

42. How Well do European Patients Understand Cancer-Associated Thrombosis? A Patient Survey

Author

Falanga A, Monreal M, Girvalaki C, Young A, Easaw Jc, and Elalamy I

Subjects
medicine.medical_specialty, Text mining, medicine.drug_class, business.industry, allergology, Anticoagulant, medicine, Cancer associated thrombosis, Patient survey, business, Intensive care medicine
Abstract

Ongoing concerns regarding the morbidity and mortality from cancer-associated thrombosis led the European Cancer Patient Coalition (ECPC), the voice of cancer patients across Europe, to create a pan-European cancer-associated awareness patient survey to assess CAT knowledge among a large population of patients with cancer. The ECPC survey represents the largest of its kind amongst patients/caregivers with CAT and identified significant gaps in patient awareness and knowledge of CAT. It also identified a need for educational CAT-related discussions and interventions between healthcare professionals and patients with cancer and their caregivers. The aim of this paper is to highlight these gaps and to provide healthcare professionals with awareness of what information should be shared with patients/caregivers as well as how and when that information should be provided. Notably, the importance of providing information on CAT risk and risk factors, how to reduce their risk of CAT, the role of anticoagulant prophylaxis and treatment (short- and long-term) including possible side-effects, and finally how to early identify CAT symptoms. Here we outline what type of information should be provided, as well as when and how to best discuss CAT with our oncology patients and their caregivers along the cancer care continuum, to reduce the risk of CAT and associated complications with a goal of improving patient outcomes.

Published
2021
Full Text
View/download PDF

43. Thrombotic storm, hemostasis disorders and thromboinflammation in COVID-19

Author

Makatsariya, A. D., primary, Slukhanchuk, E. V., additional, Bitsadze, V. O., additional, Khizroeva, J. Kh., additional, Tretyakova, M. V., additional, Shkoda, A. S., additional, Akinshina, S. V., additional, Makatsariya, N. A., additional, Tsibizova, V. I., additional, Gris, J.-C., additional, Elalamy, I., additional, Ay, С., additional, and Grandone, E., additional

Published
2021
Full Text
View/download PDF

44. Vaccine-induced immune thrombotic thrombocytopenia: definition, risks with different vaccines, and regulatory responses

Author

Akinshina, S. V., primary, Bitsadze, V. O., additional, Khizroeva, J. Kh., additional, Grigorieva, K. N., additional, Slukhanchuk, E. V., additional, Tretyakova, M. V., additional, Tsibizova, V. I., additional, Elalamy, I., additional, Gris, J.-C., additional, Brenner, B., additional, Grandone, E., additional, Ay, C., additional, and Makatsariya, A. D., additional

Published
2021
Full Text
View/download PDF

45. Neutrophil extracellular traps: a role in inflammation and dysregulated hemostasis as well as in patients with COVID-19 and severe obstetric pathology

Author

Makatsariya, A. D., primary, Slukhanchuk, E. V., additional, Bitsadze, V. O., additional, Khizroeva, J. Kh., additional, Tretyakova, M. V., additional, Makatsariya, N. A., additional, Akinshina, S. V., additional, Shkoda, A. S., additional, Pankratyeva, L. L., additional, Di Renzo, G. C., additional, Rizzo, G., additional, Grigorieva, K. N., additional, Tsibizova, V. I., additional, Gris, J.-C., additional, and Elalamy, I., additional

Published
2021
Full Text
View/download PDF

46. Features of nervous system damage in antiphospholipid syndrome

Author

Voskresenskaya, O. N., primary, Bitsadze, V. O., additional, Khizroeva, J. Kh., additional, Sukontseva, T. A., additional, Tretyakova, M. V., additional, Shkoda, A. S., additional, Gris, J.-C., additional, Elalamy, I., additional, Rizzo, G., additional, Blinov, D. V., additional, and Makatsariya, A. D., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results